STOCK TITAN
  1. Home
  2. Sec-filings
  3. OCUL
  4. [Form 4] OCULAR THERAPEUTIX, INC Insider Trading Activity

Ocular Therapeutix (OCUL) CFO awarded RSUs and stock options in new equity grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Ocular Therapeutix Chief Financial Officer Jason Shand Robins received new equity awards as part of his compensation. He was granted 15,441 restricted stock units, each representing one share of common stock, bringing his direct common stock holdings to 68,097 shares after the award. He was also granted an option to buy 14,024 shares of common stock at an exercise price of $8.74 per share, expiring in 2036. The RSUs vest over three years in three equal annual installments, and the stock option vests monthly over four years, both contingent on his continued service with the company.

Positive

  • None.

Negative

  • None.
Insider Robins Jason Shand
Role Chief Financial Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 14,024 $0.00 --
Grant/Award Common Stock 15,441 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 14,024 shares (Direct, null); Common Stock — 68,097 shares (Direct, null)
Footnotes (1)
  1. On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. Subject to the reporting person's continued service to the Corporation, the shares underlying this option vest over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.
RSUs granted 15,441 units Restricted stock units granted on June 10, 2026
Common stock holding after grant 68,097 shares Direct holdings after RSU award
Stock options granted 14,024 options Right to buy common stock granted June 10, 2026
Option exercise price $8.74 per share Strike price for 14,024-share option grant
Option expiration June 9, 2036 Expiration date of stock option grant
restricted stock units financial
"the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2021 Stock Incentive Plan financial
"granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc."
RSUs financial
"Each RSU represents a right to receive one share of the Corporation's common stock."
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
vest financial
"the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with 14,024.0000 shares at $8.7400 exercise price"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Robins Jason Shand
(Last)(First)(Middle)
C/O OCULAR THERAPEUTIX, INC.
14 CROSBY DRIVE, 3RD FLOOR
(Street)
BEDFORD MASSACHUSETTS 01730
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/10/2026A15,441(1)A$068,097D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$8.7406/10/2026A14,024 (2)06/09/2036Common Stock14,024$014,024D
Explanation of Responses:
1. On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.
2. Subject to the reporting person's continued service to the Corporation, the shares underlying this option vest over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.
/s/ Todd Anderman, Attorney-in-Fact for Jason Shand Robins06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Ocular Therapeutix (OCUL) report for Jason Shand Robins?

Ocular Therapeutix reported that CFO Jason Shand Robins received 15,441 restricted stock units and a stock option for 14,024 shares at $8.74 per share, both granted as compensation contingent on continued service.

How many Ocular Therapeutix (OCUL) shares does the CFO hold after this Form 4?

After the equity grant, CFO Jason Shand Robins directly holds 68,097 shares of Ocular Therapeutix common stock. This figure reflects his position following the 15,441 restricted stock units awarded on June 10, 2026.

What are the vesting terms of the RSUs granted to the Ocular Therapeutix (OCUL) CFO?

The 15,441 RSUs granted to the CFO vest over three years, with one-third vesting on the one-year anniversary of the June 10, 2026 grant date and additional one-thirds vesting at the end of each of the next two years.

What are the key details of the stock option granted to the Ocular Therapeutix (OCUL) CFO?

The CFO received a stock option for 14,024 shares of common stock at an exercise price of $8.74 per share, expiring on June 9, 2036. These option shares vest monthly over four years, starting one month after the grant date.

Is the Ocular Therapeutix (OCUL) CFO’s Form 4 transaction an open-market buy or a compensation grant?

The Form 4 transactions reflect compensation grants, not open-market purchases. The CFO received restricted stock units and a stock option award at no cash cost, both subject to service-based vesting rather than market transactions.